Avalon GloboCare Corp. Stock News

Advanced Disposal Services (NYSE:ADSW) and Avalon (NYSE:AWX) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of th

* Avalon Globocare (NASDAQ: AVCO) shares are trading higher on Wednesday after the company announced the commercialization and distribution agreement with Cellex for the coronavirus antibody rapid tes

In anticipation of high demand, Avalon is working with Cellex to source manufacturing facilities and develop next generation COVID-19 testing kitsFREEHOLD, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Aval

* Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on A

Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate.

A look at the shareholders of Avalon GloboCare Corp. (NASDAQ:AVCO) can tell us which group is most powerful...

- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR).

- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B..

Avalon GloboCare Corp. (AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Professor Uwe B. Sleytr to its Scientific a

University of California, San Diego researchers edited a gene called CISH from the immune system's natural killer (NK) cells, freeing up the signaling of cytokines—molecules that direct immune cells

FREEHOLD, N.J., June 11, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it.

Jun 08, 2020 (Market Insight Reports) -- Selbyville, Delaware According to Market Study Report, Provides A Detailed Overview Of Regenerative Medicine Market...

Entered Into Strategic Partnership with GensKey Medical Technology Co. Ltd. to Co-Develop and Commercialize Point-of-Care Antibody-Based IgG/IgM and PCR-Based SARS-CoV-2.

The

RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of.